SK bioscience Co.,Ltd. (KRX: 302440)

Market Cap	3.51T
Revenue (ttm)	371.48B
Net Income (ttm)	27.43B
Shares Out	78.35M
EPS (ttm)	356.51
PE Ratio	125.80
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111,079
Open	44,000
Previous Close	44,700
Day's Range	43,650 - 45,450
52-Week Range	43,650 - 73,700
Beta	1.19
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About SK bioscience Co.,Ltd.

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 984
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 302440

Financial Performance

In 2023, SK bioscience Co.,Ltd.'s revenue was 369.51 billion, a decrease of -19.10% compared to the previous year's 456.73 billion. Earnings were 22.32 billion, a decrease of -81.77%.